IP Library Granted Patent US 12,364,816
Granted Patent B2
US 12,364,816 · App. 17/180,309 · Granted Jul 22, 2025

Glucose level management based on fat content of meals

Inventors: Boyi Jiang (Pasadena, CA); Yuxiang Zhong (Arcadia, CA); Sinu Bessy Abraham (Gallatin, TN); Siddharth Arunachalam (Northridge, CA); Pratik J. Agrawal (Porter Ranch, CA)
Assignee: MEDTRONIC MINIMED, INC.
A61M5/1723G16H20/10A61M2205/52
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,364,816
App. No.
17/180,309
Granted
Jul 22, 2025
Kind
B2
Abstract

Techniques for glucose level management are disclosed. In some examples, the techniques may involve obtaining an estimated protein value for a meal and determining an equivalent carbohydrate value for the meal based on the estimated protein value. In some examples, the techniques may involve obtaining an estimated fat value for a meal and determining, based on the estimated fat value, a glucose absorption rate resulting from consumption of the meal. In some examples, the equivalent carbohydrate value and/or the glucose absorption rate may be used to determine an amount of insulin to deliver to a patient to counteract a glucose level increase caused by consumption of the meal. The techniques may further involve generating an output indicative of the amount of insulin to deliver to the patient to counteract the glucose level increase caused by consumption of the meal.

Claims (67)

1. A system comprising:

an insulin infusion device;

one or more processors; and

one or more processor-readable storage media storing instructions which, when executed by the one or more processors, cause performance of:

obtaining an estimated fat value for a meal;

determining, based on the estimated fat value, a glucose absorption rate resulting from consumption of the meal by using a patient-specific parameter to determine the glucose absorption rate that is scaled between two values;

predicting, using a patient-specific physiological simulator and based on the glucose absorption rate, amounts of glucose to be absorbed in a bloodstream of the patient and a glucose level increase over a period of time that is caused by the consumption of the meal;

determining, based on the predicted amounts of glucose to be absorbed in the bloodstream of the patient and the predicted glucose level increase over the period of time, an amount of insulin to deliver to a patient that counteracts the predicted glucose level increase over the period of time that is caused by consumption of the meal;

generating an output indicative of the amount of insulin to deliver to the patient to counteract the glucose level increase caused by consumption of the meal; and

delivering, by the insulin infusion device, the determined amount of insulin to the patient based on the output.

2. The system of claim 1 , wherein determining the amount of insulin to deliver to the patient comprises:

determining, based on the predicted amounts of glucose to be absorbed into the bloodstream, a bolus dosage of insulin to deliver to the patient.

3. The system of claim 2 , wherein determining the amount of insulin to deliver to the patient comprises:

prior to determining the bolus dosage, obtaining an amount of a basal dosage of insulin previously delivered to the patient, and wherein determining the bolus dosage is further based on the amount of the basal dosage of insulin.

4. The system of claim 2 , wherein determining the bolus dosage comprises:

identifying a plurality of candidate dosages;

for each candidate dosage of the plurality of candidate dosages, predicting a respective amount of time within a target range for the patient's glucose levels; and

selecting a candidate dosage that corresponds to a maximum amount of time within the target range.

5. The system of claim 1 , wherein determining the glucose absorption rate comprises:

determining an absorption rate tuning factor for approximating an effect of fat on the glucose absorption rate, wherein the absorption rate tuning factor is the patient-specific parameter; and

determining the glucose absorption rate based on the estimated fat value for the meal and the absorption rate tuning factor.

6. The system of claim 5 , wherein the absorption rate tuning factor is determined based on historical meal data for the patient and further based on historical glucose level data for the patient.

7. The system of claim 1 , wherein determining the amount of insulin to deliver to the patient comprises:

determining, based on the glucose absorption rate, a peak of the glucose level increase caused by consumption of the meal; and

determining, based on the peak, the amount of insulin to deliver to the patient.

8. The system of claim 1 , wherein determining the amount of insulin to deliver to the patient comprises:

determining, based on the glucose absorption rate, a timing for a peak of the glucose level increase caused by consumption of the meal; and

determining, based on the timing for the peak, the amount of insulin to deliver to the patient.

9. A processor-implemented method comprising:

obtaining an estimated fat value for a meal;

determining, based on the estimated fat value, a glucose absorption rate resulting from consumption of the meal by using a patient-specific parameter to determine the glucose absorption rate that is scaled between two values;

predicting, using a patient-specific physiological simulator and based on the glucose absorption rate, amounts of glucose to be absorbed in a bloodstream of the patient and a glucose level increase over a period of time that is caused by the consumption of the meal;

determining, based on the predicted amounts of glucose to be absorbed in the bloodstream of the patient and the predicted glucose level increase over the period of time, an amount of insulin to deliver to a patient that counteracts the predicted glucose level increase over the period of time that is caused by consumption of the meal;

generating an output indicative of the amount of insulin to deliver to the patient to counteract the glucose level increase caused by consumption of the meal; and

delivering, by an insulin infusion device, the determined amount of insulin to the patient based on the output.

10. The method of claim 9 , wherein determining the amount of insulin to deliver to the patient comprises:

determining, based on the predicted amounts of glucose to be absorbed into the bloodstream, a bolus dosage of insulin to deliver to the patient.

11. The method of claim 10 , wherein determining the amount of insulin to deliver to the patient comprises:

prior to determining the bolus dosage, obtaining an amount of a basal dosage of insulin previously delivered to the patient, and wherein determining the bolus dosage is further based on the amount of the basal dosage of insulin.

12. The method of claim 10 , wherein determining the bolus dosage comprises:

identifying a plurality of candidate dosages;

for each candidate dosage of the plurality of candidate dosages, predicting a respective amount of time within a target range for the patient's glucose levels; and

selecting a candidate dosage that corresponds to a maximum amount of time within the target range.

13. The method of claim 9 , wherein determining the glucose absorption rate comprises:

determining an absorption rate tuning factor for approximating an effect of fat on the glucose absorption rate, wherein the absorption rate tuning factor is the patient-specific parameter; and

determining the glucose absorption rate based on the estimated fat value for the meal and the absorption rate tuning factor.

14. The method of claim 13 , wherein the absorption rate tuning factor is determined based on historical meal data for the patient and further based on historical glucose level data for the patient.

15. The method of claim 9 , wherein determining the amount of insulin to deliver to the patient comprises:

determining, based on the glucose absorption rate, a peak of the glucose level increase caused by consumption of the meal; and

determining, based on the peak, the amount of insulin to deliver to the patient.

16. The method of claim 9 , wherein determining the amount of insulin to deliver to the patient comprises:

determining, based on the glucose absorption rate, a timing for a peak of the glucose level increase caused by consumption of the meal; and

determining, based on the timing for the peak, the amount of insulin to deliver to the patient.

17. One or more non-transitory processor-readable storage media storing instructions which, when executed by one or more processors, cause performance of:

obtaining an estimated fat value for a meal;

determining, based on the estimated fat value, a glucose absorption rate resulting from consumption of the meal by using a patient-specific parameter to determine the glucose absorption rate that is scaled between two values;

predicting, using a patient-specific physiological simulator and based on the glucose absorption rate, amounts of glucose to be absorbed in a bloodstream of the patient and a glucose level increase over a period of time that is caused by the consumption of the meal;

determining, based on the predicted amounts of glucose to be absorbed in the bloodstream of the patient and the predicted glucose level increase over the period of time, an amount of insulin to deliver to a patient that counteracts the predicted glucose level increase over the period of time that is caused by consumption of the meal;

generating an output indicative of the amount of insulin to deliver to the patient to counteract the glucose level increase caused by consumption of the meal; and

delivering, by an insulin infusion device, the determined amount of insulin to the patient based on the output.

18. The one or more non-transitory processor-readable storage media of claim 17 , wherein determining the glucose absorption rate comprises:

determining an absorption rate tuning factor for approximating an effect of fat on the glucose absorption rate, wherein the absorption rate tuning factor is the patient-specific parameter; and

determining the glucose absorption rate based on the estimated fat value for the meal and the absorption rate tuning factor.

19. The one or more non-transitory processor-readable storage media of claim 18 , wherein the absorption rate tuning factor is determined based on historical meal data for the patient and further based on historical glucose level data for the patient.

20. The one or more non-transitory processor-readable storage media of claim 17 , wherein determining the amount of insulin to deliver to the patient comprises:

determining, based on the glucose absorption rate, a timing for a peak of the glucose level increase caused by consumption of the meal; and

determining, based on the timing for the peak, the amount of insulin to deliver to the patient.

Assignments (2)
SECURITY INTEREST Recorded Jan 16, 2026
From: MEDTRONIC MINIMED, INC.; COMPANION MEDICAL, INC.
To: CITIBANK, N.A.
Reel/Frame 074394/0237 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 19, 2021
From: JIANG, BOYI; ZHONG, YUXIANG; ABRAHAM, SINU BESSY; ARUNACHALAM, SIDDHARTH; AGRAWAL, PRATIK J.
To: MEDTRONIC MINIMED, INC.
Reel/Frame 055340/0026 →
Continuity (1)
Related Publication 20220265926A1 · Aug 25, 2022
References Cited (63)
US 4562751A · Nason et al. · 1986 [cited by applicant]
US 4685903A · Cable et al. · 1987 [cited by applicant]
US 5080653A · Voss et al. · 1992 [cited by applicant]
US 5097122A · Colman et al. · 1992 [cited by applicant]
US 5505709A · Funderburk et al. · 1996 [cited by applicant]
US 5836312A · Moore · 1998 [cited by applicant]
US 6088608A · Schulman et al. · 2000 [cited by applicant]
US 6119028A · Schulman et al. · 2000 [cited by applicant]
US 6485465B2 · Moberg et al. · 2002 [cited by applicant]
US 6554798B1 · Mann et al. · 2003 [cited by applicant]
US 6558320B1 · Causey, III et al. · 2003 [cited by applicant]
US 6558351B1 · Steil et al. · 2003 [cited by applicant]
US 6589229B1 · Connelly et al. · 2003 [cited by applicant]
US 6641533B2 · Causey et al. · 2003 [cited by applicant]
US 6659980B2 · Moberg et al. · 2003 [cited by applicant]
US 6740072B2 · Starkweather et al. · 2004 [cited by applicant]
US 6752787B1 · Causey, III et al. · 2004 [cited by applicant]
US 6817990B2 · Yap et al. · 2004 [cited by applicant]
US 6827702B2 · Lebel et al. · 2004 [cited by applicant]
US 6932584B2 · Gray et al. · 2005 [cited by applicant]
US 7323142B2 · Pendo et al. · 2008 [cited by applicant]
US 7402153B2 · Steil et al. · 2008 [cited by applicant]
US 7621893B2 · Moberg et al. · 2009 [cited by applicant]
US 8674288B2 · Hanson et al. · 2014 [cited by applicant]
US 11723560B2 · Constantin · 2023 [cited by examiner]
US 20050187749A1 · Singley · 2005 [cited by applicant]
US 20070179434A1 · Weinert · 2007 [cited by examiner]
US 20080294373A1 · Johnson · 2008 [cited by applicant]
US 20090006061A1 · Thukral et al. · 2009 [cited by applicant]
US 20090006129A1 · Thukral et al. · 2009 [cited by applicant]
US 20120315609A1 · Miller-Kovach et al. · 2012 [cited by applicant]
US 20140066889A1 · Grosman et al. · 2014 [cited by applicant]
US 20180169333A1 · Grosman et al. · 2018 [cited by applicant]
US 20180200439A1 · Mazlish · 2018 [cited by examiner]
US 20180271455A1 · Zhong et al. · 2018 [cited by applicant]
US 20190321553A1 · Grosman et al. · 2019 [cited by applicant]
US 20190341137A1 · Chiu et al. · 2019 [cited by applicant]
US 20200098465A1 · Jiang et al. · 2020 [cited by applicant]
US 20200135320A1 · Vleugels · 2020 [cited by applicant]
US 20200268968A1 · Steil · 2020 [cited by examiner]
US 20200390973A1 · Wu et al. · 2020 [cited by applicant]
US 20210205534A1 · Jepson et al. · 2021 [cited by applicant]
US 20210294946A1 · Hendriks · 2021 [cited by examiner]
US 20220265177A1 · Jiang et al. · 2022 [cited by applicant]
AU 2014202301A1 · 2014 [cited by applicant]
CN 114949444A · 2022 [cited by applicant]
CN 114949445A · 2022 [cited by applicant]
EP 4047611A1 · 2022 [cited by applicant]
EP 4047612A1 · 2022 [cited by applicant]
WO 2019157102A1 · 2019 [cited by applicant]
Extended Search Report from counterpart European Application No. 22156942.9 dated Jul. 7, 2022, 12 pp. [cited by applicant]
Paterson et al., “Influence of Dietary Protein on Postprandial Blood Glucose Levels in Individuals with Type 1 Diabetes Mellitus Using Intensive Insulin Therapy,” Diabetic Medicine, May 2016, vol. 33, No. 5, pp. 592-598. [cited by applicant]
Bell et al., “Impact of Fat, Protein, and Glycemic Index on Postprandial Glucose Control in Type 1 Diabetes: Implications for Intensive Diabetes Management in the Continuous Glucose Monitoring Era,” Diabetes Care, vol. … [cited by applicant]
Grosman et al., “Sensor-Augmented Pump-Based Customized Mathematical Model for Type 1 Diabetes,” Diabetes Technology and Therapeutics, vol. 20, No. 3, Mar. 2018, pp. 207-221. [cited by applicant]
Fletcher et al., “Feasibility of an implanted, closed-loop, blood glucose control device”, Immunology 230, 2001, 31 pp., (Applicant points out, in accordance with MPEP 609.04(a), that the year of publication, 2001, is s… [cited by applicant]
EP Extended Search report dated Jul. 8, 2022, in U.S. Appl. No. 22/156,969. [cited by applicant]
Response to Extended Search Report dated Jul. 8, 2022, from counterpart European Application No. 22156969.2 filed Jan. 31, 2023, 18 pp. [cited by applicant]
U.S Advisory Action dated Aug. 23, 2023 in U.S. Appl. No. 17/180,268. [cited by applicant]
U.S. Final Office Action dated Jun. 2, 2023 in U.S. Appl. No. 17/180,268. [cited by applicant]
U.S. Non-Final Office Action dated Dec. 6, 2022, in U.S. Appl. No. 17/180,268. [cited by applicant]
U.S. Non-Final Office Action dated Nov. 15, 2023 in U.S. Appl. No. 17/180,268. [cited by applicant]
U.S. Advisory Action dated Aug. 30, 2024 in U.S. Appl. No. 17/180,268. [cited by applicant]
U.S. Final Office Action dated Jun. 26, 2024 in U.S. Appl. No. 17/180,268. [cited by applicant]